Literature DB >> 35639331

Lymphatic Interventions in the Cancer Patient.

Eslam Wassal Youssef1, Ahmed Aly1, Akshaar Brahmbhatt1, Amgad Moussa1, Ernesto Santos2.   

Abstract

PURPOSE OF REVIEW: The incidence of lymphatic leakage (iatrogenic and non-iatrogenic) is growing in cancer population due to the increased complexity of the surgical procedures and improved overall survival in cancer patients. The purpose of this article is to review the contemporary approach in the field of percutaneous lymphatic embolization in cancer patients with lymphatic leaks. RECENT
FINDINGS: Since the advent of intranodal lymphangiography in 2011 alongside with the MR and CT lymphangiography, the accuracy of diagnosis of the lymphatic diseases has significantly improved significantly. These advancements have triggered a revival of minimally invasive lymphatic interventions. Lymphatic embolization is expanding from the classic indication, thoracic duct embolization, to other lymphatic disorders (chylous ascites, lymphoceles, liver lymphorrhea, protein-losing enteropathy). The growth of lymphatic research and the standardization of the lymphatic interventions require a multidisciplinary and collaborative approach between physicians and researchers.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cancer patients; Chyle leak; Chylothorax; Chylous ascites; Embolization; Interventional Radiology; Intranodal lymphangiography; Lymphangiogram; Lymphatic embolization; Lymphocele; MR lymphangiography

Mesh:

Year:  2022        PMID: 35639331     DOI: 10.1007/s11912-022-01293-1

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.945


  71 in total

1.  Transhepatic lymphatic embolization of intractable hepatic lymphorrhea.

Authors:  David Guez; Gregory J Nadolski; Brian A Pukenas; Maxim Itkin
Journal:  J Vasc Interv Radiol       Date:  2014-01       Impact factor: 3.464

2.  Risk Factors for Postoperative Chylothorax After Radical Subtotal Esophagectomy.

Authors:  Yu Ohkura; Masaki Ueno; Junichi Shindoh; Toshiro Iizuka; Hairin Ka; Harushi Udagawa
Journal:  Ann Surg Oncol       Date:  2018-07-11       Impact factor: 5.344

3.  An analysis of the risk factors and management of lymphocele after pelvic lymphadenectomy in patients with gynecologic malignancies.

Authors:  Hee Yeon Kim; Jae Wook Kim; Sung Hoon Kim; Young Tae Kim; Jae Hoon Kim
Journal:  Cancer Res Treat       Date:  2004-12-31       Impact factor: 4.679

4.  Lymphangiography and Lymphatic Embolization for the Treatment of Refractory Chylous Ascites.

Authors:  Gregory J Nadolski; Nikunj R Chauhan; Maxim Itkin
Journal:  Cardiovasc Intervent Radiol       Date:  2017-12-13       Impact factor: 2.740

5.  Lymphangiography and Lymphatic Embolization for the Management of Pelvic Lymphocele After Radical Prostatectomy in Prostatic Cancer.

Authors:  Hee Ho Chu; Ji Hoon Shin; Jong Woo Kim; Seung Yeon Noh; Woo Jin Yang; Suyoung Park
Journal:  Cardiovasc Intervent Radiol       Date:  2019-03-27       Impact factor: 2.740

6.  Intranodal CT Lymphangiography with Water-soluble Iodinated Contrast Medium for Imaging of the Central Lymphatic System.

Authors:  Suhag Patel; Saebeom Hur; Tamim Khaddash; Scott Simpson; Maxim Itkin
Journal:  Radiology       Date:  2021-10-26       Impact factor: 11.105

7.  Management of chyle leakage after general thoracic surgery: Impact of thoracic duct embolization.

Authors:  Yeong Jeong Jeon; Jong Ho Cho; Dongho Hyun; Sumin Shin; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Jae Ill Zo; Young Mog Shim
Journal:  Thorac Cancer       Date:  2021-03-30       Impact factor: 3.500

8.  Chylous ascites in colorectal surgery: A systematic review.

Authors:  Zi Qin Ng; Margaret Han; Han Nien Beh; Simon Keelan
Journal:  World J Gastrointest Surg       Date:  2021-06-27

Review 9.  Chylous Ascites: Evaluation and Management.

Authors:  Said A Al-Busafi; Peter Ghali; Marc Deschênes; Philip Wong
Journal:  ISRN Hepatol       Date:  2014-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.